scholarly journals Orotidylate Decarboxylase Inhibitor

2020 ◽  
Author(s):  
Keyword(s):  
Decarboxylase Inhibitor

Changes in serotonin contents in brain affect metabolic heat production of rabbits in cold

1978 ◽  
Vol 235 (1) ◽  
pp. R41-R47
Author(s):  
M. T. Lin ◽  
I. H. Pang ◽  
S. I. Chern ◽  
W. Y. Chia
Keyword(s):  
Blood Flow ◽  
Amino Acid ◽  
Heat Loss ◽  
Acid Decarboxylase ◽  
Evaporative Heat Loss ◽  
Decarboxylase Inhibitor ◽  
Ambient Temperatures ◽  
Amino Acid Decarboxylase ◽  
Metabolic Heat ◽  
Normal Limits

Elevating serotonin (5-HT) contents in brain with 5-hydroxytryptophan (5-HTP) reduced rectal temperature (Tre) in rabbits after peripheral decarboxylase inhibition with the aromatic-L-amino-acid decarboxylase inhibitor R04-4602 at two ambient temperatures (Ta), 2 and 22 degrees C. The hypothermia was brought about by both an increase in respiratory evaporative heat loss (Eres) and a decrease in metabolic rate (MR) in the cold. At a Ta of 22 degrees C, the hypothermia was achieved solely due to an increase in heat loss. Depleting brain contents of 5-HT with intraventricular, 5,7-dihydroxytryptamine (5,7-DHT) produced an increased Eres and ear blood flow even at Ta of 2 degrees C. Also, MR increased at all but the Ta of 32 degrees C. However, depleting the central and peripheral contents of 5-HT with p-chlorophenylalanine (pCPA) produced lower MR accompanied by lower Eres in the cold compared to the untreated control. Both groups of pCPA-treated and 5,7-DHT-treated animals maintained their Tre within normal limits. The data suggest that changes in 5-HT content in brain affects the MR of rabbits in the cold. Elevating brain content of 5-HT tends to depress the MR response to cold, while depleting brain content of 5-HT tends to enhance the MR response to cold.

scholarly journals Experimental Fecal Transmission of Human Cryptosporidia to Pigs, and Attempted Treatment with an Ornithine Decarboxylase Inhibitor

1982 ◽  
Vol 19 (6) ◽  
pp. 700-707 ◽  
Author(s):  
H. W. Moon ◽  
A. Schwartz ◽  
M. J. Welch ◽  
P. P. McCann ◽  
P. L. Runnels
Keyword(s):  
Ornithine Decarboxylase ◽  
Potassium Dichromate ◽  
Colonic Epithelium ◽  
Fecal Material ◽  
Decarboxylase Inhibitor ◽  
Apparent Effect ◽  
Newborn Pigs

Fecal material collected from an immunologically deficient man with persistent cryptosporidia infection was stored in potassium dichromate for two weeks and then fed (inoculated) to newborn pigs. The six inoculated newborn pigs shed the organism in their feces starting four to five days after inoculation and continuing for as long as 22 days after inoculation. Pigs which were killed and necropsied while shedding had cryptosporidia infection of ileum, cecum, and colon. Infected pigs had atrophied ileal villi and flattened irregular cecal and colonic epithelium. Uninoculated littermate controls remained free of the infection and had histologically normal intestinal tracts at necropsy. Treatment of three of the six inoculated pigs with the ornithine decarboxylase inhibitor, DL- α-difluoromethylornithine, orally for ten days had no apparent effect on the infection.

Dopamine agonists for parkinson’s disease

1991 ◽  
Vol 29 (2) ◽  
pp. 7-8
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Therapeutic Efficacy ◽  
Dopamine Agonists ◽  
Dopa Decarboxylase ◽  
Decarboxylase Inhibitor ◽  
Duration Of Action ◽  
Motor Disability ◽  
The Uk

Bromocriptine, lysuride (formerly lisuride, Revanil – Roche) and pergolide (not yet marketed in the UK) are dopamine agonists developed for use in the treatment of patients with Parkinson’s disease. Combination of a dopamine agonist with levodopa plus a dopa-decarboxylase inhibitor (‘co-dieldopa’)* may have advantages at all stages of the disease. The aim of combined co-dieldopa + agonist treatment is to limit some of the problems with prolonged co-dieldopa use alone; especially fluctuations in motor disability.1 It is still not clear how the three agonists compare with each other for therapeutic efficacy, duration of action, and side effects, nor how they are best combined with co-dieldopa.

Influences of Catecholamine Contents on Tetrahydrobiopterin Metabolism

Pteridines ◽  
1998 ◽  
Vol 9 (1) ◽  
pp. 39-43
Author(s):  
Hiroshi Kuzuya ◽  
Hideo Sakamoto ◽  
Ko Fujita
Keyword(s):  
Nerve Growth Factor ◽  
The Other ◽  
Acid Decarboxylase ◽  
Catecholamine Metabolism ◽  
Decarboxylase Inhibitor ◽  
Amino Acid Decarboxylase ◽  
Comt Inhibitor ◽  
Dopamine Content ◽  
Pheochromocytoma Pc12 ◽  
Inhibitor Treatment

Summary The influence of changes in catecholamine metabolism on tetrahydrobiopterin biosynthesis was investigated in cultured rat pheochromocytoma PC12 cells. The increase in the cellular dopamine content after treatment with the MAO-COMT inhibitor or dopamine produced decreases in the GTP-cy-clohydrolase I (GTPCH-I) activity and total biopterin content. On the contrary, the catecholamine increase after treatment with nerve growth factor produced increases in the GTPCH -I activity and total biopterin content. On the other hand, the decrease in the dopamine content after tyrosine hydroxylase (TH) inhibitor treatment produced decreases in the GTPCH-I activity and total biopterin content, but the catecholamine decrease (the DOPA content increased about 3.4-fold) after aromatic L-amino acid decarboxylase inhibitor treatment produced a decrease in the GTPCH-I activity. These results suggest that an increase in dopamine content that is not directly related to the action of TH plays a role in down-regulation of tetrahydrobiopterin biosynthesis and that when the changes in catecholamine metabolism are strongly associated with the action of TH, tetrahydrobiopterin biosynthesis is regulated depending on the necessity for TH.

Treatment of two mastocytosis patients with a histidine decarboxylase inhibitor

1985 ◽  
Vol 16 (3-4) ◽  
pp. 244-248 ◽  
Author(s):  
G. Granerus ◽  
J. H. Olafsson ◽  
G. Roupe
Keyword(s):  
Histidine Decarboxylase ◽  
Decarboxylase Inhibitor

Combination Therapy of Extrapyramidal Disease with Trihexyphenidyl and L-Dopa

1979 ◽  
Vol 7 (1) ◽  
pp. 19-28 ◽  
Author(s):  
H Hökendorf
Keyword(s):  
Side Effects ◽  
Combination Therapy ◽  
Motor System ◽  
Good Control ◽  
Decarboxylase Inhibitor ◽  
System Disease ◽  
Extrapyramidal Disease ◽  
Extrapyramidal Motor

An electromyographic method was used to study the effect of combination therapy with L-dopa and trihexyphenidyl on tremor in thirty patients suffering from extrapyramidal motor system disease. In this method tremor activity was measured and documented so that the course of the disease could be followed objectively. L-dopa alone was slightly more effective against tremor than was trihexyphenidyl alone. The combination of the two drugs was more effective than either drug used alone, and its side-effects were mild and definitely fewer than had been reported with L-dopa combined with a decarboxylase inhibitor. Good control of tremor with L-dopa and trihexyphenidyl was obtained clinically and verified electromyographically.

Sign in / Sign up

Export Citation Format

Share Document